Award recordCONTRACT

TRAVERE THERAPEUTICS, INC.

PIID 36C25024P0081· VHA· 250-NETWORK CONTRACT OFFICE 10 (36C250)· 3650 · CHEMICAL AND PHARMACEUTICAL PRODUCTS MANUFACTURING MACHINERY· FY2024· $236,500 net obligations· UEI JUBZMHK84S36· CA

Description

CHENODAL 250MG (CHENODIOL) PHARMACEUTICAL

First action · last action
2023-10-10 · 2023-10-12
Transactions
2
First transaction's obligation
$236,500
Base + all options value (sum of deltas)
$236,500
Extent competed
NOT COMPETED
Other than full & open authority
URGENCY (FAR 6.302-2)
Set-aside
NO SET ASIDE USED.
Offers received
1
SDVOSB flag on record
No
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING

Modification chain · 2 transactions

Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.

$236,500$0Base award · 2023-10-10 · this action $236,500 · running total $236,500Modification P00001 · 2023-10-12 · this action $0 · running total $236,500
  • Base2023-10-10+$236,500= $236,500
  • Mod P000012023-10-12+$0= $236,500
TransactionAction dateThis action (delta)Running totalDescription on this transaction
Base2023-10-10+$236,500$236,500CHENODAL 250MG (CHENODIOL) PHARMACEUTICAL
Mod P00001· OTHER ADMINISTRATIVE ACTION2023-10-12+$0$236,500CHENODAL 250MG (CHENODIOL) PHARMACEUTICAL

Related awards · 11

Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.

Other VA awards to the same recipient (UEI JUBZMHK84S36)

AwardOffice · PSC / listingNet obligationsFY
36C24526N0794245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS$15,867FY2026
36C24526N0779245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS$33,372FY2026
36C24526N0725245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS$15,867FY2026
36C24526N0675245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS$15,867FY2026
36C24526N0571245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS$33,372FY2026
36C24526N0554245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS$17,667FY2026

Other recipients under 3650 from 250-NETWORK CONTRACT OFFICE 10 (36C250) (most recent first)

AwardRecipientOfficeNet obligationsFY
36C25025N0791OMNICELL, INC.250-NETWORK CONTRACT OFFICE 10 (36C250)$51,789FY2025
36C25025P0648MIRUM PHARMACEUTICALS, INC.250-NETWORK CONTRACT OFFICE 10 (36C250)$231,717FY2025
36C25024N0401OMNICELL, INC.250-NETWORK CONTRACT OFFICE 10 (36C250)$51,789FY2024
36C25024F0711SCRIPTPRO USA INC250-NETWORK CONTRACT OFFICE 10 (36C250)$143,301FY2024
36C25023F1112SCRIPTPRO USA INC250-NETWORK CONTRACT OFFICE 10 (36C250)$1,249,957FY2023

Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_36C25024P0081_3600_-NONE-_-NONE- · retrieved 2026-09-26.